RxDoctor Payments Data

Joseph Saucedo, DO

Family Medicine · Corsicana, TXNPI 1164485140

Payments from drug & device makers

$2,690in general payments, 2019–2025

Across 129 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$966
  • Novo Nordisk$713
  • Lilly USA, LLC$168
  • Amarin Pharma, Inc.$117
  • Pfizer$116
  • Bayer$107
  • plus $504 from 14 others

What the payments were for

  • Food & beverage$2,690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,690 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$132,826
Medicare patients
179
Services billed
3,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide51$56,169
FarxigaDapagliflozin Propanediol33$33,889
EliquisApixaban28$18,194
TrulicityDulaglutide12$11,411
JanuviaSitagliptin Phosphate12$11,072
BrilintaTicagrelor23$9,963
TradjentaLinagliptin16$9,746
JardianceEmpagliflozin11$8,837
Janumet XrSitagliptin Phos/Metformin Hcl12$8,611
VascepaIcosapent Ethyl17$6,866
Rosuvastatin Calcium426$6,293
Atorvastatin Calcium558$5,948
Budesonide14$5,761
Montelukast Sodium272$3,955
Levothyroxine Sodium356$3,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$713$56,16951 claims
AstraZenecaFarxiga, Brilinta$966$43,85256 claims
MerckJanuvia, Janumet Xr$98$19,68324 claims
Boehringer IngelheimTradjenta, Jardiance$29$18,58327 claims
PfizerEliquis$116$18,19428 claims
Lilly USA, LLCTrulicity$168$11,41112 claims
AbbVieSynthroid$64$1,92133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Corsicana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →